Vertex beats estimates and adds $200 million to sales guidance

5 August 2022
vertex_large

US biopharma Vertex Pharmaceuticals (Nasdaq: VRTX) beat the expectations of Wall Street analysts with its sales and earnings figures for the second quarter of 2022.

The company’s quarterly revenues came in at a net total of $2.2 billion, a 22% increase on the same period of 2021 and 3% above the consensus estimate.

Adjusted diluted earnings per share were $3.60, which was in excess of the consensus and SVB Securities expectations and a 16% rise on a year ago.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical